Patent ID: 11913956
Assignee: SHANDONG ZEJI BIOTECHNOLOGY CO., LTD.
Field: Measurement (Instruments)
Classification: CPC G  C | IPC G

Claim 2:
3. A method for an identification of therapeutic efficacy of tumor treatment, comprising:
obtaining blood samples from a subject at a first time and a second time;
determining a concentration of GAPDH in each of the blood samples by a sandwich ELISA; and
comparing the concentration of GAPDH in the blood samples at the first time and the second time,
wherein when the concentration of GAPDH in the blood sample at the second time is lower than that at the first time, and a percentage of decrease reaches or exceeds a set reference value, then it is determined that the therapeutic treatment is effective;
wherein when the concentration of GAPDH in the blood sample at the second time is increased in comparison to that at the first time, is not significantly different from that at the first time or a percentage of increase does not reach or exceed the set reference value, then it is determined that the therapeutic treatment is not effective,
wherein the first time and the second time are respectively a beginning and an end of a period; or the first time and the second time are respectively before and after receiving a treatment,
wherein the set reference value is 30%,
wherein an amino acid sequence of GAPDH is shown as SEQ ID No. 1, the sandwich ELISA is performed by a capture antibody and a detection antibody, the capture antibody binds to N-terminal amino acids 40-160 of the GAPDH amino acid sequence for capturing GAPDH from each of the blood samples, and the detection antibody binds to N-terminal amino acids 180-335 of the GAPDH amino acid sequence for measuring the concentration of GAPDH,
wherein the capture antibody comprises heavy chain variable region and light chain variable region, the heavy chain variable region comprises CDR1 shown as SEQ ID No. 2, CDR2 shown as SEQ ID No. 3 and CDR3 shown as SEQ ID No. 4, the light chain variable region comprises CDR1 shown as SEQ ID No. 5, CDR2 shown as SEQ ID No. 6 and CDR3 shown as SEQ ID No. 7,
the detection antibody comprises heavy chain variable region and light chain variable region, the heavy chain variable region comprises CDR1 shown as SEQ ID No. 8, CDR2 shown as SEQ ID No. 9 and CDR3 shown as SEQ ID No. 10, the light chain variable region comprises CDR1 shown as SEQ ID No. 11, CDR2 shown as SEQ ID No. 12 and CDR3 shown as SEQ ID No. 13.